NEWS

FIRST PATIENT SUCCESSFULLY DOSED

The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.

TENBORON FEATURED ON FINNISH BIOINDUSTRIES’ WEBSITE

Tenboron’s background and BNCT technology are presented in this post:

https://www.suomenbioteollisuus.fi/post/finnish-company-tenboron-develops-groundbreaking-cancer-treatment

Patient recruitment starts for Phase I clinical trial

Study preparations have been completed and necessary permits obtained.

Data from the first patient(s) expected in Q1/2024.

Tenboron to present at the LSX Nordic Congress 

Tenboron is a showcase company in this year’s LSX Nordic Congress which takes place in Copenhagen, Denmark on October 10-11.

TENBORON’S LEAD MOLECULE ENTERS CLINICAL STAGE

The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.
The study will be conducted at the Helsinki University Hospital.
Preparations for study initiation are underway.

This website uses cookies to ensure that we give you the best experience on our website.